Efthymios Manolis

Implementation of proteomic biomarkers: making it work

Harald Mischak, John P. A. Ioannidis, Àngel Argilés et al. · European Journal of Clinical Investigation · 2012 · 168 citations · Full text

Valid Biomarkers, Proteomic Technology, Biomarker (Medicine) +20

Scientific and regulatory evaluation of mechanistic <i>in silico</i> drug and disease models in drug development: Building model credibility

Flora T. Musuamba, Ine Skottheim Rusten, R Lesage et al. · CPT Pharmacometrics & Systems Pharmacology · 2021 · 133 citations · Full text

Engineering, Risk Model Validation, Verification +24

Proposals for model‐based paediatric medicinal development within the current European Union regulatory framework

Efthymios Manolis, Gérard Pons · British Journal of Clinical Pharmacology · 2009 · 124 citations · Full text

Drug Safety, Translational Medicine, Pharmacokinetic Modeling +14

Model‐Informed Drug Discovery and Development: Current Industry Good Practice and Regulatory Expectations and Future Perspectives

Scott Marshall, Rajanikanth Madabushi, Efthymios Manolis et al. · CPT Pharmacometrics & Systems Pharmacology · 2018 · 119 citations · Full text

Preclinical Therapeutics, Future Perspectives, Us Food +18

Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function

Nassim Kamar, Étienne Chatelut, Efthymios Manolis et al. · American Journal of Kidney Diseases · 2004 · 81 citations

Ribavirin Pharmacokinetics, Renal Function, Hepatology +9